Maximizing Success

Presented By:

Supported by an unrestricted educational grant from Tibotec

System Requirements

The following are required to view these programs:

• OS X or later
• Safari/Mozilla 1.5

• Flash Player 9
• Broadband (Cable/DSL or higher)

To View Programs Online, Please Read the Following
Information and Scroll Down to the bottom of the Page

About the Program

• Program Overview
• Learning Objectives
• Intended Audience
• Accreditation Statement
• Credit Designation Statement
• Course Directors
• National Faculty
• Instructions for Obtaining Continuing Medical Education Credit
• Faculty Disclosure

Program Overview

This program features:

• A presidential-style debate, with John Bartlett MD as moderator and Cal Cohen MD, Paul Sax MD, Edwin DeJesus MD and Rick Elion MD as discussants. The debate will explore many of the current controversies in HIV treatment including how to balance the likelihood of success and the potential consequences of failure, the importance of NNRTI resistance and side effects, factors affecting PI selection, and the role of newer antiretrovirals.

• 6 clinical cases, presented by a distinguished faculty, that will explore the issues discussed in the debate program in more detail and place these issues into a clinical context.

• A group round table, moderated by John Bartlett MD, during which controversial issues surrounding antiretroviral therapy are discussed by the program faculty.

This program is sponsored for CME credit by The Johns Hopkins University School of Medicine. The information in this educational activity was planned and produced in accordance with ACCME Essentials.  All content was prepared by a distinguished faculty.  This program is for health care providers who treat HIV-positive patients, there are no prerequisites. 

Presented By:

Supported by an unrestricted educational grant from Tibotec

Back to Top

Learning Objectives and Program Details

Upon completion of this CME activity, the participant should be able to:

1. Integrate and discuss the clinical use and balancing of drug, regimen and patient characteristics that have been demonstrated to be predictive of ARV treatment success
2. Analyze current clinical trial data on treatment of ARV-naïve patients and use this information to select ARV drugs and regimens that maximize the chance for virologic success and minimize the risk of loss of future treatment options
3. Analyze current clinical trial data on treatment of ARV-experienced patients and use this information to select ARV drugs and regimens that maximize the chance for virologic success and minimize the risk of loss of future treatment options
4. Gain a further understanding of the role resistance plays in ARV drug and regimen failure, and be able to use this understanding in clinical practice to construct ARV regimens that improve patient treatment outcomes and preserve future treatment options

Release Date: January 21, 2009
Expiration Date: January 21, 2010

Estimated time to complete this activity:
• Lecture/Debate 1.5 hours
• Clinical Cases 3.0 hours (.5 hours per case) 
• Faculty Group Discussion 1.0 hour

The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of the CME activity 

Intended Audience

This activity is intended for physicians, physicians' assistants, and advanced practice nurses and other healthcare professionals involved in the treatment and management of patients with HIV infection. There are no prerequisites.

Back to Top

Accreditation Statement

The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

Lecture/Debate
The John Hopkins University School of Medicine designates this activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Clinical Cases
The John Hopkins University School of Medicine designates this activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Each clinical case is designated for .5 AMA PRA Category 1 Credit™.

Faculty Group Round Table
The John Hopkins University School of Medicine designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Course Directors

John Bartlett, MD
Professor of Medicine,
Johns Hopkins School of Medicine
Baltimore, Maryland

Calvin J. Cohen, MD, MS
Research Director, CRI New England
Clinical Instructor, Harvard Medical School
Boston, Massachusetts

National Faculty

Brian Boyle, MD, JD
Medical Training Chair,
International Center for Equal Healthcare Access
Medical Editor, HIVandHepatitis.com
Stockton, New Jersey

Rafael E. Campo, MD
Professor of Clinical Medicine
Division of Infectious Diseases
University of Miami School of Medicine
Jackson Memorial Hospital
Miami, Florida

Eric Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine,
David Geffen School of Medicine at UCLA
Los Angeles, California

Edwin DeJesus, MD
Medical Director,
Orlando Immunology Center
Orlando, Florida

Richard A. Elion, MD
Associate Professor of Clinical Medicine,
George Washington University Medical Center
Washington, DC

Ian Frank, MD
Associate Professor of Medicine,
Director, Antiretroviral Clinical Research
University of Pennsylvania
Philadelphia, Pennsylvania

Trevor Hawkins, MD
Associate Professor, University of New Mexico
Medical Director, Southwest CARE Center
Santa Fe, New Mexico

Graeme J. Moyle, MD, MB, BS
Associate Director of HIV Research,
Chelsea & Westminster Hospital
London, England

Paul Sax, MD
Clinical Director,
Brigham and Women’s Division
of Infectious Diseases and HIV Program
Associate Professor of Medicine,
Harvard Medical School
Boston, Massachusetts

Luther A. Virgil, Jr., MD
Chief Medical Officer,
National Minority Clinical Research Association (NMCRA)
Fairfield, New Jersey

Instructions for Obtaining Continuing Medical Education Credit

In order to receive credit, participants must view the entire activity and complete a post test and activity evaluation online. Upon a successful score of 70% on the post test and completion of the evaluation, participants may print out their certificate. Participants may access the post test and evaluation for each activity by the links below.

• Lecture/Debate
• Faculty Group Round Table
• Patient Case by Calvin Cohen MD
• Patient Case by Paul Sax MD
• Patient Case by Luther Virgil MD
• Patient Case by Rafael Campo MD
• Patient Case by Richard Elion MD
• Patient Case by Edwin DeJesus MD

Faculty Disclosure

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following disclosure information:   

Dr. John Bartlett:

• Sources of Funding for Research: Gilead
• Consulting Agreements: Bristol-Myers Squibb; Tibotec; Abbott; GlaxoSmithKline
• Speakers' Bureau/Honorarium Agreements: None
• Financial Interests/Stock Ownership: None
• Other: None 

Dr. Brian Boyle:

• Sources of Funding for Research: None.
• Consulting Agreements: None.
• Speakers' Bureau/Honorarium Agreements: None.
• Financial Interests/Stock Ownership: None.
• Other: ViralEd, LLC. 

Dr. Calvin Cohen:

• Sources of Funding for Research: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Roche; Pfizer; Tibotec.
• Consulting Agreements: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Roche; Pfizer; Tibotec.
• Speakers' Bureau/Honorarium Agreements: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Roche; Pfizer; Tibotec; Virco.
• Financial Interests/Stock Ownership: None.
• Other: ViralEd, LLC. 

Dr. Rafael Campo:

• Sources of Funding for Research: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer
• Consulting Agreements: Abbott; Merck; Tibotec; Vicro
• Speakers' Bureau/Honorarium Agreements: Abbott; Gilead; Merck; Pfizer; Tibotec; Virco
• Financial Interests/Stock Ownership: Wife is an employee of Merck
• Other: Dr. Campo's wife is a Manager with Merck's Health Management Services group for Tennessee, Louisiana, Florida, and Puerto Rico.  She is responsible for the asthma and diabetes disease areas; however, she does not have responsibility for any of Merck's anti-infective, antiviral, or vaccine products

Dr. Eric Daar:

• Sources of Funding for Research: Abbott; Merck; GlaxoSmithKline; Pfizer; Gilead
• Consulting Agreements: Abbott; Boerhringer Ingelheim; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer; Monogram; Pathway; Oncolysis; Tibotec
• Speakers' Bureau/Honorarium Agreements: GlaxoSmithKline; Merck
• Financial Interests/Stock Ownership: None
• Other: None

Dr. Edwin DeJesus:

• Sources of Funding for Research: Boehringer Ingelheim; Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Roche; Pfizer; Tibotec; Merck; Schering Plough
• Consulting Agreements: Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Roche; Vertex
• Speakers' Bureau/Honorarium Agreements: Boehringer Ingelheim; Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Roche; Pfizer; Tibotec; Schering Plough
• Financial Interests/Stock Ownership: None
• Other: None

Dr. Richard A. Elion:

• Sources of Funding for Research: Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Incyte; Tibotec.
• Consulting Agreements: Bristol-Myers Squibb Company; Gilead Sciences, Inc.; GlaxoSmithKline; Incyte; Panacos.
• Speakers' Bureau/Honorarium Agreements: None.
• Financial Interests/Stock Ownership: None.  
• Other: ViralEd, LLC.

Dr. Ian Frank:

• Sources of Funding for Research: Bavarian Nordic; Merck; Tibotec.
• Consulting Agreements: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer; Tibotec.
• Speakers' Bureau/Honorarium Agreements: Abott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Tibotec.
• Financial Interests/Stock Ownership: None.
• Other: None. 

Dr. Trevor Hawkins:

• Sources of Funding for Research: Gilead; GlaxoSmithKline; Tibotec; Pfizer; NAPO
• Consulting Agreements: Bristol-Myers Squibb; Gilead; Pfizer
• Speakers' Bureau/Honorarium Agreements: Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer; Tibotec; Virco
• Financial Interests/Stock Ownership: None
• Other: None

Dr. Graeme Moyle:

• Sources of Funding for Research: Abbott; Arnomed; Ardea; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer; Tibotec.
• Consulting Agreements: Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer; Panacos; Tobira; Tibotec.
• Speakers' Bureau/Honorarium Agreements: Bristol-Myers Squibb; Boehringer-Ingelheim; Gilead; GlaxoSmithKline; Merck; Pfizer; Tibotec.
• Financial Interests/Stock Ownership: None.
• Other: ViralEd, LLC.

Dr. Paul Sax:

• Sources of Funding for Research: Bristol-Myers Squibb; Merck; Pfizer.
• Consulting Agreements: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline.
• Speakers' Bureau/Honorarium Agreements: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Tibotec; Virco.
• Financial Interests/Stock Ownership: None. 
• Other: None.

Dr. Luther Virgil:

• Sources of Funding for Research: None
• Consulting Agreements: Abbott; Gilead
• Speakers' Bureau/Honorarium Agreements: Abbott; Gilead
• Financial Interests/Stock Ownership: None
• Other: None

No speaker has indicated that their presentation will include information on off-label products. 

Opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME program. CME collects only the information necessary to provide you with the services that you request.

Copyright © 2008 The Johns Hopkins University School of Medicine. All rights reserved.